Advertisement

Der Radiologe

, Volume 58, Issue 8, pp 746–753 | Cite as

Normalgewebe: Strahlenempfindlichkeit, Toxizität, Konsequenzen für die Planung

  • A. Rühle
  • P. E. Huber
Leitthema
  • 135 Downloads

Zusammenfassung

Die Radiotherapie gehört zusammen mit der Chirurgie, Chemotherapie und neuerdings der Immuntherapie zu den elementaren Säulen der Krebstherapie. Zunehmend in den Fokus der modernen Krebstherapie rückt die Lebensqualität der Patienten, die in besonderem Maße von den akuten und späten Normalgewebsreaktionen nach der Tumortherapie abhängt. Aufgrund verbesserter Heilungsraten für Krebs in den vergangenen Jahrzehnten gewinnen dabei besonders die Spätreaktionen der Radiotherapie an Bedeutung. Ein tiefgreifendes Verständnis der radiogenen Normalgewebsreaktionen erlaubt eine suffiziente Diagnose und spezifische Therapie der Nebenwirkungen und damit eine Verbesserung der Lebensqualität der Patienten. In diesem Beitrag werden Normalgewebsreaktionen verschiedener Organsysteme unter Berücksichtigung der Strahlenbiologie behandelt sowie vorhandene und zukünftige Möglichkeiten zur Behandlung von Strahlennebenwirkungen diskutiert.

Schlüsselwörter

Tumor Radiotherapie Bestrahlung Nebenwirkungen Lebensqualität 

Normal tissue: radiosensitivity, toxicity, consequences for planning

Abstract

Along with chemotherapy, surgery and immunotherapy, radiotherapy is a mainstay of cancer treatment. Considering the improving survival rates for various malignancies during the past decades, the importance of radiation-induced late normal tissue response is increasing. Quality of life is becoming an important issue in modern cancer treatment and is correlated with acute and late normal tissue response after radiotherapy. A profound understanding of radiation-induced normal tissue response is necessary to sufficiently diagnose and treat radiation-induced side effects and thereby increase the patients’ quality of life. Here, the various normal tissue responses in consideration of the radiation biology are specified and prospective options to attenuate radiation-induced side effects are discussed.

Keywords

Tumors Radiotherapy Ionizing radiation Side effects Quality of life 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

A. Rühle und P. E. Huber geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Welzel T, Tanner JM (2018) Nebenwirkungen nach Strahlentherapie in der Bildgebung. Radiologe 58.  https://doi.org/10.1007/s00117-018-0412-6 PubMedGoogle Scholar
  2. 2.
    Sterzing F et al (2009) Intensity modulated radiotherapy (IMRT) in the treatment of children and adolescents—a single institution’s experience and a review of the literature. Radiat Oncol 4:37PubMedPubMedCentralGoogle Scholar
  3. 3.
    Askoxylakis V et al (2016) Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis. Radiat Oncol 11:17PubMedPubMedCentralGoogle Scholar
  4. 4.
    Nutting CM et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12(2):127–136PubMedPubMedCentralGoogle Scholar
  5. 5.
    Hall EJ, Wuu C‑S (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56(1):83–88PubMedGoogle Scholar
  6. 6.
    Zwicker F et al (2015) In vivo measurement of dose distribution in patients’ lymphocytes: helical tomotherapy versus step-and-shoot IMRT in prostate cancer. J Radiat Res 56(2):239–247PubMedGoogle Scholar
  7. 7.
    Nicolay NH et al (2016) High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer: experience from a large single-center cohort. Strahlenther Onkol 192(7):458–466PubMedGoogle Scholar
  8. 8.
    Roeder F et al (2016) Intraoperative electron radiation therapy combined with external beam radiation therapy and limb sparing surgery in extremity soft tissue sarcoma: a retrospective single center analysis of 183 cases. Radiother Oncol 119(1):22–29PubMedGoogle Scholar
  9. 9.
    Hoffmann M et al (2015) Long term results of postoperative intensity-modulated radiation therapy (IMRT) in the treatment of squamous cell carcinoma (SCC) located in the oropharynx or oral cavity. Radiat Oncol 10:251PubMedPubMedCentralGoogle Scholar
  10. 10.
    Roeder F et al (2014) Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol 9:191PubMedPubMedCentralGoogle Scholar
  11. 11.
    Thieke C et al (2015) Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol 10(1):267PubMedPubMedCentralGoogle Scholar
  12. 12.
    Miralbell R et al (2002) Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 54(3):824–829PubMedGoogle Scholar
  13. 13.
    Durante M, Debus Heavy Charged Particles J (2018) Does improved precision and higher biological effectiveness translate to better outcome in patients? Semin Radiat Oncol 28(2):160–167PubMedGoogle Scholar
  14. 14.
    Jensen AD et al (2016) High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years’ experience with raster-scanned carbon ion therapy. Radiother Oncol 118(2):272–280PubMedGoogle Scholar
  15. 15.
    Jensen AD et al (2015) Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival. Cancer 121(17):3001–3009PubMedGoogle Scholar
  16. 16.
    Uhl M et al (2014) Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results. Cancer 120(21):3410–3417PubMedGoogle Scholar
  17. 17.
    Huber PE et al (2001) Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol 59(2):161–167PubMedGoogle Scholar
  18. 18.
    Emami B et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122PubMedGoogle Scholar
  19. 19.
    Lawrence YR et al (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76(3 Suppl):S20–S27PubMedPubMedCentralGoogle Scholar
  20. 20.
    Wenz F et al (2000) Prospective evaluation of delayed central nervous system (CNS) toxicity of hyperfractionated total body irradiation (TBI). Int J Radiat Oncol Biol Phys 48(5):1497–1501PubMedGoogle Scholar
  21. 21.
    Hempen C, Weiss E, Hess CF (2002) Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10(4):322–328PubMedGoogle Scholar
  22. 22.
    Kirkpatrick JP et al (2011) Estimating normal tissue toxicity in radiosurgery of the CNS: application and limitations of QUANTEC. J Radiosurg SBRT 1(2):95–107PubMedPubMedCentralGoogle Scholar
  23. 23.
    Huber PE et al (2001) Transient enlargement of contrast uptake on MRI after linear accelerator (linac) stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 49(5):1339–1349PubMedGoogle Scholar
  24. 24.
    Combs SE et al (2013) Skull base meningiomas: long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiother Oncol 106(2):186–191PubMedGoogle Scholar
  25. 25.
    Combs SE et al (2005) Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys 63(1):75–81PubMedGoogle Scholar
  26. 26.
    Saleh-Ebrahimi L et al (2013) Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer—a retrospective single center analysis. Radiat Oncol 8:20PubMedPubMedCentralGoogle Scholar
  27. 27.
    Henson BS et al (2001) Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 37(1):84–93PubMedGoogle Scholar
  28. 28.
    Stephens LC et al (1991) Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer 67(6):1539–1543PubMedGoogle Scholar
  29. 29.
    Wang X, Eisbruch A (2016) IMRT for head and neck cancer: reducing xerostomia and dysphagia. J Radiat Res 57(Suppl 1):i69–i75PubMedPubMedCentralGoogle Scholar
  30. 30.
    Munter MW et al (2007) Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int J Radiat Oncol Biol Phys 67(3):651–659PubMedGoogle Scholar
  31. 31.
    Bras J, de Jonge HKT, van Merkesteyn JPR (1990) Osteoradionecrosis of the mandible: pathogenesis. Am J Otolaryngol 11(4):244–250PubMedGoogle Scholar
  32. 32.
    Zwicker F et al (2011) Reirradiation with intensity-modulated radiotherapy in recurrent head and neck cancer. Head Neck 33(12):1695–1702PubMedGoogle Scholar
  33. 33.
    Coggle JE, Lambert BE, Moores SR (1986) Radiation effects in the lung. Environ Health Perspect 70:261–291PubMedPubMedCentralGoogle Scholar
  34. 34.
    Roeder F et al (2010) Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer. Strahlenther Onkol 186(3):149–156PubMedGoogle Scholar
  35. 35.
    Guckenberger M et al (2013) Safety and efficacy of stereotactic body radiotherapy for stage I non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 8(8):1050–1058PubMedGoogle Scholar
  36. 36.
    Catane R et al (1979) Pulmonary toxicity after radiation and bleomycin: a review. Int J Radiat Oncol Biol Phys 5(9):1513–1518PubMedGoogle Scholar
  37. 37.
    Pearson D et al (1978) The interaction of actinomycin D and radiation. Int J Radiat Oncol Biol Phys 4(1):71–73PubMedGoogle Scholar
  38. 38.
    Cuzick J et al (1987) Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep 71(1):15–29PubMedGoogle Scholar
  39. 39.
    Weberpals J et al (2018) Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J.  https://doi.org/10.1093/eurheartj/ehy167 PubMedGoogle Scholar
  40. 40.
    Schultz-Hector S, Trott K‑R (2007) Radiation-induced cardiovascular diseases: Is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 67(1):10–18PubMedGoogle Scholar
  41. 41.
    Halyard MY et al (2009) Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 27(16):2638PubMedPubMedCentralGoogle Scholar
  42. 42.
    Classen J et al (1998) Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Strahlenther Onkol 174:82–84PubMedGoogle Scholar
  43. 43.
    Dawson LA et al (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53(4):810–821PubMedGoogle Scholar
  44. 44.
    Russell AH et al (1993) Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the rtog dose escalating protocol. Int J Radiat Oncol Biol Phys 27(1):117–123PubMedGoogle Scholar
  45. 45.
    Andratschke N et al (2018) The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 18(1):283PubMedPubMedCentralGoogle Scholar
  46. 46.
    Pan CC et al (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76(3):S94–S100PubMedPubMedCentralGoogle Scholar
  47. 47.
    Dawson LA et al (2010) Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys 76(3, Supplement):S108–S115PubMedGoogle Scholar
  48. 48.
    Cheng JC, Schultheiss TE, Wong JY (2008) Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. Int J Radiat Oncol Biol Phys 71(5):1436–1443PubMedGoogle Scholar
  49. 49.
    Crew JP, Jephcott CR, Reynard JM (2001) Radiation-induced haemorrhagic cystitis. Eur Urol 40(2):111–123PubMedGoogle Scholar
  50. 50.
    Nicolay NH et al (2015) Mesenchymal stem cells—a new hope for radiotherapy-induced tissue damage? Cancer Lett 366(2):133–140PubMedGoogle Scholar
  51. 51.
    Nicolay NH et al (2015) Radio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinic. Oncotarget 6(23):19366–19380PubMedPubMedCentralGoogle Scholar
  52. 52.
    Lalu MM et al (2012) Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE 7(10):e47559PubMedPubMedCentralGoogle Scholar
  53. 53.
    Chapel A et al (2013) New insights for pelvic radiation disease treatment: multipotent stromal cell is a promise mainstay treatment for the restoration of abdominopelvic severe chronic damages induced by radiotherapy. World J Stem Cells 5(4):106–111PubMedPubMedCentralGoogle Scholar
  54. 54.
    Rühle A et al (2018) The radiation resistance of human multipotent mesenchymal stromal cells is independent of their tissue of origin. Int J Radiat Oncol Biol Phys 100(5):1259–1269PubMedGoogle Scholar
  55. 55.
    Nicolay NH et al (2013) Mesenchymal stem cells retain their defining stem cell characteristics after exposure to ionizing radiation. Int J Radiat Oncol Biol Phys 87(5):1171–1178PubMedGoogle Scholar
  56. 56.
    Abdollahi A et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201(6):925–935PubMedPubMedCentralGoogle Scholar
  57. 57.
    Flechsig P et al (2012) LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 18(13):3616–3627PubMedGoogle Scholar
  58. 58.
    Dadrich M et al (2016) Combined inhibition of TGFbeta and PDGF signaling attenuates radiation-induced pulmonary fibrosis. Oncoimmunology 5(5):e1123366PubMedGoogle Scholar
  59. 59.
    Bickelhaupt S et al (2017) Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djw339 PubMedGoogle Scholar
  60. 60.
    Gorina E et al (2017) PRAISE, a randomized, placebo-controlled, double-blind phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients. Eur Respiratory Soc 50:OA3400.  https://doi.org/10.1183/1393003.congress-2017.OA3400 Google Scholar
  61. 61.
    Sternlicht MD et al (2018) Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab. Respir Res 19(1):14PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung für RadioOnkologie und StrahlentherapieUniversitätsklinik HeidelbergHeidelbergDeutschland
  2. 2.KKE Molekulare und RadioOnkologieDeutsches Krebsforschungszentrum (dkfz)HeidelbergDeutschland

Personalised recommendations